Orexo, inVentiv Health partner for commercialization of Zubsolv in US
Sweden-based pharmaceutical firm Orexo has announced that Orexo US and inVentiv Health have entered into a new partnership agreement for the commercialization of Zubsolv in the US.
Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for the maintenance treatment of opioid dependence.
The drug should be used as part of a comprehensive treatment plan, which includes counseling and psychosocial support.
The new deal, which has three year term, replaces existing contracts and will become effective 01 July 2014.
Under the new deal, Orexo will take the leadership and control of all commercial functions to ensure the efficient and agile governance of the commercialization of Zubsolv.
Consequently Orexo will directly employ the sales managers as well as take over leadership and day to day management of field-based promotional activities.
The deal will see inVentiv Health take responsibility of employing and supporting the individual sales representatives.
Orexo chief executive officer Nikolaj Sørensen said with the new partnership structure the company will increase the control of the sales operations to ensure Zubsolv gains the attention and focus required to maximize the potential.
"With the new structure in place we will be able to act much more swiftly in the market and we see this as a natural next step in the evolution of Orexo and an important driver of growth," Sørensen said.
The new deal calls for Orexo to cover direct sales force expenses from inVentiv Health.
As a consequence of the new deal structure the expenses for the sales organization will be reported as a selling expense from the second quarter of 2014.
The company said that there will be a limited one-time transition expense reported in the second quarter, associated with the change of partner.
From the third quarter of 2014, there will be no further expenses related to the previous partnership, the company said.